
|Articles|February 18, 2013
Dispute Develops Over Discount Drug Program
Advertisement
When a private oncology practice in Memphis formed a partnership with a nearby hospital in late 2011, the organizations proclaimed that the deal would “transform cancer care” in the region.
What they did not emphasize was that the deal would also create a windfall for them worth millions of dollars a year, courtesy of an obscure federally mandated drug discount program.
Read the full story:
Source: The New York Times
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show Most CRS, ICANS Cases Happen Within 15 Days of Liso-Cel Infusion
2
Real-World Usage of Nintedanib for PPF Differs From Trial Settings
3
Long-Term Adalimumab Improves Work, Life Quality in Psoriasis
4
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
5













































